To appraise the clinical and cost effectiveness of brentuximab vedotin within its marketing authorisation for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma.
Status In progress
Process STA pre-2018
ID number 1190

Provisional Schedule

Committee meeting: 1 27 November 2018
Expected publication 22 May 2019

Project Team

Project lead Stephanie Callaghan

Email enquiries


Key events during the development of the guidance:

Date Update
06 December 2017 In progress, In progress
05 December 2017 This appraisal is to be rescheduled to allow the company (Takeda) additional time to incorporate important information into their submission, including a new commercial arrangement. A new deadline for submissions (previously 7 December 2017) and committee date will be confirmed in due course.
12 October 2017 Invitation to participate
24 July 2017 - 21 August 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
26 July 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance